New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy.

摘要: This review aims to overview and critically analyses recent developments in achieving tumour-specific delivery of anticancer agents, maximizing efficacy, mitigating tumour progression off-target effects. Stemming from critical needs develop target-specific vehicles cancer therapy, various hyaluronic acid (HA)-conjugated nanomedicines have been fabricated owing their biocompatibility, safety, targetability drugs genes, proficient interaction with cluster-determinant-44 (CD44) receptors over-expressed on the surface cells. HA-based conjugation or modulation encapsulated nanocarriers shown promising efficacy against types carcinomas liver, breast, colorectal, pancreatic, lung, skin, ovarian, cervical, head neck gastric. The success this emerging platform is assessed rapid internalization payloads into cells, impeding cells division proliferation, induction cancer-specific apoptosis prevention metastasis (tumour progression). extends detailed insight engineering nanomedicines, characterization, utilization for diagnosis treatment CD44 over-expressing subtypes emphasizing transition clinical therapy.